Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arbaclofen Placarbil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | PTGFR | P43088 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen Placarbil SCHEMBL2472988 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL638204 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL351833 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL349961 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14692761 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689524 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689601 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL12130896 | 0.91 | MAPT (0.39) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL13101899 | 0.91 | MAPT (0.40) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL2230566 | 0.91 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | claimed |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | XENOPORT, INC. (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | GABRB2, GABRB3, GABBR2 | GABBR2 3/4885GABBR1 5/4885LMNA 4249/4885 |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | GABRB2, GABRB3, GABBR2 | GABBR2 3/4885GABBR1 5/4885LMNA 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.